–News Direct–
Oncimmune CEO Martin Gouldstone joined Steve Darling from Proactive to announce the company's interim results for the six months ended February 29, 2024. During this period, Oncimmune achieved revenue of 1.19 million, marking a significant milestone in the company's financial performance. This revenue surpasses the 1.15 million generated from continuing operations in the entire fiscal year 2023, indicating a notable improvement and reflecting a strategic shift initiated in October 2023.
Gouldstone expressed satisfaction with the company's performance in the first half of fiscal year 2024, highlighting the substantial increase in revenues compared to the ImmunoINSIGHTSTM business in fiscal year 2023. This achievement underscores the effectiveness of Oncimmune's new strategic approach and commercial endeavors, which are gaining momentum.
Moreover, Gouldstone revealed that Oncimmune secured contracts for seven new projects during the reporting period. These contracts are expected to be completed by the end of fiscal year 2024, contributing to the company's revenue growth trajectory. Additionally, Oncimmune entered into a Master Services Agreement with Freenome, further enhancing its commercial portfolio.
Looking ahead, Oncimmune is well-positioned for continued growth, with 15 new commercial opportunities in the proposal stage as of April 2024. These opportunities represent a total weighted pipeline value exceeding 2.5 million. While some revenue is anticipated to be recognized in fiscal year 2024, the majority is expected in fiscal year 2025, reflecting the company's ongoing expansion efforts and future revenue prospects.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/oncimmune-reports-robust-interim-results-exceeding-previous-years-revenue-in-just-six-months-417739559
Oncimmune Holdings PLC
COMTEX_452846485/2655/2024-05-24T12:33:23
The information contained in this post is for general information purposes only. The information is provided by Oncimmune Reports Robust Interim Results, Exceeding Previous Year’s Revenue in Just Six Months and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose.